Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

• Published in: Blood Vol. 109; no. 9; pp. 3658 - 3666
• Main Authors: Cornelissen, Jan J., van Putten, Wim L.J., Verdonck, Leo F., Theobald, Matthias, Jacky, Emanuel, Daenen, Simon M.G., van Marwijk Kooy, Marinus, Wijermans, Pierre, Schouten, Harry, Huijgens, Peter C., van der Lelie, Hans, Fey, Martin, Ferrant, Augustin, Maertens, Johan, Gratwohl, Alois, Lowenberg, Bob
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 01.05.2007; The Americain Society of Hematology
• Subjects: Adolescent; Adult; Age Factors; Biological and medical sciences; Disease-Free Survival; Female; Follow-Up Studies; Hematologic and hematopoietic diseases; Hematopoietic Stem Cell Transplantation - mortality; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute - mortality; Leukemia, Myeloid, Acute - therapy; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Living Donors; Male; Medical sciences; Meta-Analysis as Topic; Middle Aged; Recurrence; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning - mortality; Transplantation, Homologous; Human; HLA-System; Middle age; Hematology; Stem cell; Major histocompatibility system; Hematopoietic cell; Homograft; Malignant hemopathy; Sibling; Donor; Young adult; Graft; Myelosuppression; Remission; Comparative study; Acute myelocytic leukemia

The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (pts) with acute myeloid leukemia (AML) in first remission (CR1) entered in 3 consecutive studies according to a donor versus no-d...